Abstract
Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutations, leukemia specific antigens and signal transduction pathways has ushered in a new era of therapy. In many circumstances the response rates with such targeted or antibody-based therapies are superior to those achieved with standard therapy and with decreased toxicity. In this review we discuss novel therapies in AML with a focus on two major areas of unmet need: (1) single agent and combination strategies to improve frontline therapy in elderly patients with AML and (2) molecularly targeted therapies in the frontline and salvage setting in all patients with AML.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 433-445 |
| Number of pages | 13 |
| Journal | Expert Review of Hematology |
| Volume | 9 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 3 2016 |
| Externally published | Yes |
Keywords
- AML
- clinical trials
- molecular therapy
- monoclonal antibodies
- multikinase inhibitors
ASJC Scopus subject areas
- Hematology
Fingerprint
Dive into the research topics of 'Acute myeloid leukemia: advancing clinical trials and promising therapeutics'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS